Results 151 to 160 of about 171,498 (339)
Hyaluronidase Activity in the Skin, Rheumatic Disease, and Salicylates [PDF]
E. Sherwood Jones
openalex +1 more source
LACK156‐173 is internalized into RA‐FLSs via CAPN2‐mediated endocytosis and inhibits the aggressive phenotype of RA‐FLSs by restoring dysregulated fatty acid synthesis metabolism mediated by overexpressed FASN. The findings suggest that targeting the restoration of fatty acid metabolism could potentially alleviate synovial invasion and joint damage in ...
Jianling Su+17 more
wiley +1 more source
Objective A simple, scalable tool that identifies psoriasis patients at high risk for developing psoriatic arthritis (PsA) could improve early diagnosis. We aimed to develop a risk prediction model for the development of PsA and to assess its performance among patients with psoriasis.
Lihi Eder+8 more
wiley +1 more source
RHD elimination: action needed beyond secondary prophylaxis
Kate Hardie+2 more
doaj +1 more source
This study uses gut microbiome data to predict corticosteroid response in patients with immune thrombocytopenia (ITP). Fecal samples from 212 patients with ITP are sequenced. Six machine‐learning algorithms are used to train predictive models. The support vector machine‐based model integrated clinical data and selected microbial species, diversities ...
Feng‐Qi Liu+38 more
wiley +1 more source
Social and Economic Conditions and the Incidence of Rheumatic Heart Disease [PDF]
G. H. Daniel
openalex +1 more source
Implantable Self‐Powered Systems for Electrical Stimulation Medical Devices
In this paper, the design strategy and clinical application of ISS are discussed in depth from four aspects: the design and optimization of the energy collection module, the selection and preparation of adaptive electrode materials, the innovation of system design strategy, and the biological effect of electrical stimulation of ISS.
Xi Cui, Li Wu, Chao Zhang, Zhou Li
wiley +1 more source
Cortisone Therapy Mainly Applied to the Rheumatic Diseases [PDF]
J. H. Glyn
openalex +1 more source
A patented GSK‐3β inhibitor (GSK‐3βi), new benzothiazepinone compounds (BTZs), YC‐4‐3, can modulate the inflammatory status of macrophages in primary immune thrombocytopenia (ITP), and improve the thrombocytopenia in murine ITP models by directly interacting with endoplasmic reticulum (ER) stress response.
Pengcheng Xu+10 more
wiley +1 more source